Brainstorm Cell Therapeutics Inc. BCLI
We take great care to ensure that the data presented and summarized in this overview for BRAINSTORM CELL THERAPEUTICS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCLI
View all-
Vanguard Group Inc Valley Forge, PA1.4MShares$616,4360.0% of portfolio
-
Black Rock Inc. New York, NY489KShares$215,2970.0% of portfolio
-
Geode Capital Management, LLC Boston, MA357KShares$157,0980.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$149,6660.04% of portfolio
-
Weaver Consulting Group199KShares$87,7160.04% of portfolio
-
Caldwell Sutter Capital, Inc. Sausalito, CA157KShares$69,0830.0% of portfolio
-
Abner Herrman & Brock LLC146KShares$64,0200.01% of portfolio
-
Raymond James & Associates St Petersburg, FL114KShares$50,0650.0% of portfolio
-
Gsa Capital Partners LLP London, X0111KShares$48,9420.01% of portfolio
-
State Street Corp Boston, MA96.1KShares$42,2660.0% of portfolio
Latest Institutional Activity in BCLI
Top Purchases
Top Sells
About BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Insider Transactions at BCLI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Hartoun Hartounian EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
May 28
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+1.27%
|
$0
$0.52 P/Share
|
|
May 22
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+2.13%
|
$0
$0.64 P/Share
|
|
May 21
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+2.17%
|
$0
$0.58 P/Share
|
|
May 13
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.9%
|
$0
$0.49 P/Share
|
|
May 11
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.91%
|
$0
$0.47 P/Share
|
|
May 10
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+1.82%
|
$0
$0.46 P/Share
|
|
May 07
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+5.89%
|
$0
$0.37 P/Share
|
|
May 06
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+11.96%
|
$0
$0.38 P/Share
|
|
Apr 19
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+1.72%
|
$0
$0.52 P/Share
|
|
Apr 18
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,072
+12.0%
|
$0
$0.53 P/Share
|
|
Apr 17
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+15.14%
|
$0
$0.55 P/Share
|
|
Mar 11
2024
|
Alla Patlis Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,246
+50.0%
|
-
|
|
Mar 11
2024
|
Uri Yablonka EVP & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,426
+46.29%
|
-
|
|
Mar 11
2024
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
241,935
+36.36%
|
-
|
|
Mar 11
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
305,198
+33.77%
|
-
|
|
Sep 01
2023
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,500
+5.96%
|
$11,500
$1.77 P/Share
|
|
Aug 02
2023
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+17.07%
|
-
|
|
Aug 02
2023
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,185
+9.61%
|
-
|
|
Jun 19
2023
|
Nir Naor Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,999
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.38M shares |
|---|---|
| Open market or private purchase | 11.5K shares |